185 related articles for article (PubMed ID: 29274361)
1. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
[TBL] [Abstract][Full Text] [Related]
2. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
3. Lusutrombopag: First Global Approval.
Kim ES
Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
[TBL] [Abstract][Full Text] [Related]
4. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Xie CY; Xu YP; Zhao HB; Lou LG
Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
[TBL] [Abstract][Full Text] [Related]
6. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E; Miyakawa Y; Yamane A; Okamoto S
Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
[TBL] [Abstract][Full Text] [Related]
7. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
9. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.
Ng AP; Kauppi M; Metcalf D; Hyland CD; Josefsson EC; Lebois M; Zhang JG; Baldwin TM; Di Rago L; Hilton DJ; Alexander WS
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5884-9. PubMed ID: 24711413
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.
Xie C; Zhao H; Bao X; Fu H; Lou L
J Cell Mol Med; 2018 Nov; 22(11):5367-5377. PubMed ID: 30156363
[TBL] [Abstract][Full Text] [Related]
11. Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease.
Shimizu R; Katsube T; Wajima T
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):489-499. PubMed ID: 33797208
[TBL] [Abstract][Full Text] [Related]
12. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling.
Lebois M; Dowling MR; Gangatirkar P; Hodgkin PD; Kile BT; Alexander WS; Josefsson EC
J Thromb Haemost; 2016 Sep; 14(9):1882-7. PubMed ID: 27344013
[TBL] [Abstract][Full Text] [Related]
13. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.
Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T; Nakahata T
Eur J Haematol; 2009 Apr; 82(4):247-54. PubMed ID: 19183407
[TBL] [Abstract][Full Text] [Related]
14. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis.
Nakamura T; Miyakawa Y; Miyamura A; Yamane A; Suzuki H; Ito M; Ohnishi Y; Ishiwata N; Ikeda Y; Tsuruzoe N
Blood; 2006 Jun; 107(11):4300-7. PubMed ID: 16484588
[TBL] [Abstract][Full Text] [Related]
15. Novel chemical-structure TPOR agonist, TMEA, promotes megakaryocytes differentiation and thrombopoiesis via mTOR and ERK signalings.
Jiang X; Sun Y; Yang S; Wu Y; Wang L; Zou W; Jiang N; Chen J; Han Y; Huang C; Wu A; Zhang C; Wu J
Phytomedicine; 2023 Feb; 110():154637. PubMed ID: 36610353
[TBL] [Abstract][Full Text] [Related]
16. Autocrine role of angiopoietins during megakaryocytic differentiation.
Saulle E; Guerriero R; Petronelli A; Coppotelli E; Gabbianelli M; Morsilli O; Spinello I; Pelosi E; Castelli G; Testa U; Coppola S
PLoS One; 2012; 7(7):e39796. PubMed ID: 22792187
[TBL] [Abstract][Full Text] [Related]
17. Milestones in understanding platelet production: a historical overview.
Kuter DJ
Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL.
Nishino T; Miyaji K; Ishiwata N; Arai K; Yui M; Asai Y; Nakauchi H; Iwama A
Exp Hematol; 2009 Nov; 37(11):1364-1377.e4. PubMed ID: 19744539
[TBL] [Abstract][Full Text] [Related]
19. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.
Shin J; Kim MJ; Quan X; Kim JW; Lee S; Park S; Jeong JY; Yea K
BMC Cancer; 2023 May; 23(1):490. PubMed ID: 37259024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
